Scholar Rock (SRRK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Four Class II directors are nominated for election to serve until the 2029 Annual Meeting or until a successor is duly elected and qualified.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 is proposed.
Advisory approval of named executive officer compensation is included as a non-binding proposal.
Other business may be addressed at the annual meeting or any adjournments.
Board of directors and corporate governance
Director nominees for election are David Hallal, Kristina Burow, Michael Gilman, and Katie Peng.
Elected directors will serve until the 2029 Annual Meeting or until a successor is elected and qualified.
Executive compensation and say-on-pay
Shareholders are asked to approve, on an advisory basis, the compensation of named executive officers.
Latest events from Scholar Rock
- FDA accepted apitegromab BLA; net loss rose, cash reserves strong for 2026 launches.SRRK
Q1 20267 May 2026 - 2026 launches are on track, with strong liquidity and managed regulatory and supply risks.SRRK
Q4 20251 May 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance.SRRK
Proxy filing23 Apr 2026 - BLA resubmission for Apitegromab offers dual approval paths and strong launch readiness.SRRK
Status update31 Mar 2026 - Apitegromab targets a 2026 U.S. launch after regulatory delays, with global expansion and strong financials.SRRK
Leerink Global Healthcare Conference 202628 Mar 2026 - Preparing for global SMA launches with strong clinical data and expanded pipeline.SRRK
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - 2026 launches for apitegromab expected after facility remediation, with global expansion planned.SRRK
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Transformational SMA data and robust launch plans set the stage for 2025 and pipeline growth.SRRK
Piper Sandler 36th Annual Healthcare Conference3 Feb 2026 - Transformative clinical milestones in SMA and obesity set the stage for commercial success.SRRK
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026